Navigation Links
R-Tech Ueno Notifies R&D Items
Date:7/30/2009

pattern alopecia. We intend to proceed with negotiations for affiliation in Japan and abroad in the future. We also plan to newly develop this drug indicated for eyelash hypotrichosis.

5. Development code RTU-1096 (dermatological and neurological diseases)

This compound newly developed by R-Tech Ueno demonstrates an unconventional action, VAP-1* inhibition. We intend to develop this compound as a drug indicated for atopic dermatitis, contact dermatitis and psoriasis vulgaris in the dermatological field, and diabetic neuropathy in the neurological field.

We plan to report on the development status of each item on the home page of R-Tech Ueno.

*VAP-1 inhibitor

Vascular adhesion protein-1 (VAP-1) is also called semicarbazide-sensitive amine oxidase (SSAO). There are two types of VAP-1/SSAO, that is, the membrane-binding type present in the vascular endothelium and the free type present in the serum. The former serves as a molecule adherent to white blood cells and lymphocytes and is involved in inflammation while the latter detoxifies amine in the living body by its amine oxidase activity. In other words, VAP-1 is a protein that demonstrates two different functions. The increase in VAP-1/SSAO activity is observed in the serum and various tissues of patients with diabetes mellitus, atopic dermatitis, obesity, arteriosclerosis, heart disease, etc. In this regard, VAP-1 inhibitor inhibits the excessive function of VAP-1/SSAO.

About R-Tech Ueno, Ltd.

    Representative Director & President: Yukihiko Mashima
    Head Office: 1-1-7 Uchisaiwai-cho, Chiyoda-ku, Tokyo
    Code No.4573, Osaka Securities Exchange; Hercules


    CONTACT:  Koji Nakamura
              Business Management Department
              R-Tech Ueno, Ltd.
              Tel: +81-3-3596-8011
              e-mail: koji.na
'/>"/>

SOURCE R-Tech Ueno, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Extraordinary General Meetings Statement - XTL Notifies NASDAQ of Compliance with Marketplace Rule 4350(d)(2)
2. AMEX Notifies Signalife That It Has Accepted Signalifes Plan of Compliance
3. AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement
4. Boston Scientific Announces First Quarter Special Items
5. Arpida Announces Agenda Items for Shareholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
(Date:12/24/2014)... Dec. 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... on December 22, 2014, thereby completing the U.S. ... the acquisition of the Company by Merck KGaA, ... satisfies another condition to closing the transaction, which ...
(Date:12/24/2014)... and NEW YORK , Dec. ... its open-label pilot study of mazindol in children with ... and Therapy in December 2014 . ... in children with attention deficit/hyperactivity disorder" ( Konofal et ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows that ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... over the Badger state pavilion at the annual BIO convention ... visit the New York State exhibit to breathe gardenia-scented oxygen ... has grown to be as competitive as biotechnology, most states, ... the crowd. Welcome to the world of bio-branding. , ,Wisconsins ...
... DEMOletter know that I've written regularly about so- called social ... columns have run under titles such as "I'm LinkedIn - ... networks to both user and investor. I wasn't being critical, ... model for these services. , ,But in recent weeks, ...
... is currently undergoing a historical transformation. Such ... War I, when the paper, brewing, automotive and ... , ,The change from an agriculture and manufacturing-based ... is inevitable. Wisconsin now finds itself competing ...
Cached Biology Technology:Whats in a name? Quite a bit, when youre competing in biotech 2Social networks and my big a-ha 2Social networks and my big a-ha 3Social networks and my big a-ha 4Educate, innovate and execute: Wisconsins model for success 2Educate, innovate and execute: Wisconsins model for success 3
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:12/3/2014)... , Dec. 2, 2014 As part of ... Inception Technologies is pleased to announce the release of ... customers to collect the workforce data that they need. ... have been left by existing readers. Many such devices ... connectivity and modern technology. Older models force users to ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2
... 35 headwater basins in the United States and Canada found ... was less than expected in many locations, suggesting that some ... The study was just published in a special issue ... Ecological Research (LTER) network of 26 sites around the country ...
... new Rice University study this week in the journal Science ... -- from the realms of tectonic plates down to molecular bonds ... below ground. "Everything throughout history shows us that Earth does ... said Rice geochemist Cin-Ty Lee, the lead author of the study. ...
... New England is expected to experience a "moderate" regional ... in the Gulf of Maine to study the toxic algae ... no direct threat to human beings, however the toxins they ... clams which can cause paralytic shellfish poisoning (PSP) in humans ...
Cached Biology News:Impact of warming climate doesn't always translate to streamflow 2Copper chains: Study reveals Earth's deep-seated hold on copper 2Copper chains: Study reveals Earth's deep-seated hold on copper 3Researchers report potential for a 'moderate' New England 'red tide' in 2012 2Researchers report potential for a 'moderate' New England 'red tide' in 2012 3Researchers report potential for a 'moderate' New England 'red tide' in 2012 4
Mouse VEGF R1/Flt-1 Allophycocyanin MAb (Clone 141522) Keywords: Receptor Tyrosine Kinase, RTK, VEGFR1, VEGF Receptor 1 Protein Family: Receptor Tyrosine Kinases, VEGF/PDGF Family...
Evi-1 Antibody Shipping Temperature: Cold Storage Temperature: -20C...
Immunogen: Synthetic peptide: N(171) H G F L S A D Q QL I K(183) Storage: -20 C, Avoid Freeze/Thaw Cycles...
HIV-1 TAT (vN-21)...
Biology Products: